GoAI
Get started
Editas Medicine, Inc. logo

Editas Medicine, Inc.

EDIT

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.11

+$0.17 · +5.78%

Aug 21, 4:00 PM ET

EDIT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

60

Fair Value

Momentum

69

Gaining

Sentiment

42

Mixed

Risk resilience

33

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Gilmore O'Neill
Listed since
Feb 3, 2016
Employees
87

Market position

Day range

Current $3.11

52-week range

Current $3.11

Open
$2.985
Previous close
$2.94
Volume
2.12M
0.91× average
Average volume
2.33M
Average daily volume
Market cap
477.27M USD
Beta
2.06
Market reference 1
50-day average
$2.9084
+6.93% above average
200-day average
$2.5876
+20.19% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
111.99M USD
P/E (TTM)
-4.16×
P/B (TTM)
3.52×
P/S (TTM)
10.15×
EV / EBITDA
-0.75×
Earnings yield
-87.98%
Free cash flow yield
-91.16%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
56.90%
Operating margin
-174.71%
Net margin
-157.32%
Return on equity
-586.56%
Return on assets
-85.81%
Return on invested capital
-65.65%

Financial health

Debt / equity
0.15×
Current ratio
3.54×
Altman Z-score
-7.75
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends225%-274%-772%-1271%Gross margin, FY2021: 80.22%Gross margin, FY2022: 67.85%Gross margin, FY2023: 92.24%Gross margin, FY2024: -516.60%Gross margin, FY2025: 100.00%Operating margin, FY2021: -756.13%Operating margin, FY2022: -1146.26%Operating margin, FY2023: -216.56%Operating margin, FY2024: -777.22%Operating margin, FY2025: -245.15%Net margin, FY2021: -753.61%Net margin, FY2022: -1118.26%Net margin, FY2023: -196.13%Net margin, FY2024: -733.72%Net margin, FY2025: -395.01%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 80.22%. Gross margin FY2022 67.85%. Gross margin FY2023 92.24%. Gross margin FY2024 -516.60%. Gross margin FY2025 100.00%. Operating margin FY2021 -756.13%. Operating margin FY2022 -1146.26%. Operating margin FY2023 -216.56%. Operating margin FY2024 -777.22%. Operating margin FY2025 -245.15%. Net margin FY2021 -753.61%. Net margin FY2022 -1118.26%. Net margin FY2023 -196.13%. Net margin FY2024 -733.72%. Net margin FY2025 -395.01%.

Income trends

Revenue

40.52M USD+25.39%

Operating income

−99.34M USD+60.45%

Net income

−160.06M USD+32.49%
Income trends across reported periods111.05M USD−20.66M USD−152.37M USD−284.08M USDRevenue, FY2021: 25.54M USDRevenue, FY2022: 19.71M USDRevenue, FY2023: 78.12M USDRevenue, FY2024: 32.31M USDRevenue, FY2025: 40.52M USDOperating income, FY2021: −193.15M USDOperating income, FY2022: −225.95M USDOperating income, FY2023: −169.18M USDOperating income, FY2024: −251.15M USDOperating income, FY2025: −99.34M USDNet income, FY2021: −192.5M USDNet income, FY2022: −220.43M USDNet income, FY2023: −153.22M USDNet income, FY2024: −237.09M USDNet income, FY2025: −160.06M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 25.54M USD. Revenue FY2022 19.71M USD. Revenue FY2023 78.12M USD. Revenue FY2024 32.31M USD. Revenue FY2025 40.52M USD. Operating income FY2021 −193.15M USD. Operating income FY2022 −225.95M USD. Operating income FY2023 −169.18M USD. Operating income FY2024 −251.15M USD. Operating income FY2025 −99.34M USD. Net income FY2021 −192.5M USD. Net income FY2022 −220.43M USD. Net income FY2023 −153.22M USD. Net income FY2024 −237.09M USD. Net income FY2025 −160.06M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue40.52M USD32.31M USD78.12M USD19.71M USD25.54M USD
Cost of goods sold—199.25M USD6.06M USD6.34M USD5.05M USD
Gross profit40.52M USD−166.93M USD72.06M USD13.38M USD20.49M USD
Research and development89.95M USD199.25M USD177.65M USD174.96M USD142.51M USD
Selling, general, and administrative49.9M USD71.99M USD69.65M USD70.7M USD76.18M USD
Operating expenses139.86M USD84.22M USD241.24M USD239.33M USD213.64M USD
Interest income8.31M USD14.06M USD17.57M USD5.52M USD607K USD
Interest expense6.17M USD————
Depreciation and amortization5.28M USD5.81M USD6.06M USD6.34M USD5.05M USD
Operating income−99.34M USD−251.15M USD−169.18M USD−225.95M USD−193.15M USD
Net income−160.06M USD−237.09M USD−153.22M USD−220.43M USD−192.5M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+1.98%
11 comparable reports
Latest EPS result
-0.15
Estimate -0.27 · Beat by 44.55%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.05-0.36-0.68-0.99Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 5, 2025: actual -0.55, estimate -0.39, surprise -41.03%, Miss. Q2 2025, reported May 12, 2025: actual -0.92, estimate -0.564, surprise -63.13%, Miss. Q3 2025, reported Aug 12, 2025: actual -0.63, estimate -0.41, surprise -53.66%, Miss. Q4 2025, reported Nov 10, 2025: actual -0.28, estimate -0.38, surprise +26.32%, Beat. Q1 2026, reported Mar 9, 2026: actual -0.06, estimate -0.27, surprise +77.78%, Beat. Q2 2026, reported May 5, 2026: actual -0.26, estimate -0.3, surprise +13.33%, Beat. Q3 2026, reported Aug 5, 2026: actual -0.15, estimate -0.271, surprise +44.55%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.22, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates33M22.18M11.36M544.21KQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 5, 2025: actual 30.6M USD, estimate 640.25K USD, surprise +4680.01%, Beat. Q2 2025, reported May 12, 2025: actual 4.66M USD, estimate 641.91K USD, surprise +625.65%, Beat. Q3 2025, reported Aug 12, 2025: actual 3.58M USD, estimate 1.82M USD, surprise +97.05%, Beat. Q4 2025, reported Nov 10, 2025: actual 7.54M USD, estimate 8.45M USD, surprise -10.77%, Miss. Q1 2026, reported Mar 9, 2026: actual 24.74M USD, estimate 8.35M USD, surprise +196.33%, Beat. Q2 2026, reported May 5, 2026: actual 2.83M USD, estimate 6.37M USD, surprise -55.58%, Miss. Q3 2026, reported Aug 5, 2026: actual 11.89M USD, estimate 2.85M USD, surprise +317.74%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate 4.49M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$5.00

60.77% upside
Past 12 months12-month forecastHigh $6.00Average $5.00Low $4.00

Rating distribution

25 ratings
Strong buy00%
Buy1456%
Hold936%
Sell28%
Strong sell00%

Recent analyst actions

12 institutions
Jones TradingupgradeHoldBuy

EDIT news

zacks.com

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.

Read source
globenewswire.com

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a)…

Read source
globenewswire.com

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic…

Read source
forbes.com

The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

Read source
fool.com

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.

Read source
globenewswire.com

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will…

Read source

EDIT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding EDIT

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
12.62M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
7.63M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
3.1M
Weight
0.03%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.96M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
2.48M
Weight
0.02%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.45M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
1.4M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
1.2M
Weight
0.01%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%

Continue in GoAI

Research EDIT

research.disclaimer